Why CGM

A new standard of diabetes care

Reduction of Both A1C and Hypoglycemia

Real-time continuous glucose monitoring (RT-CGM) is the only diabetes management tool proven to reduce A1C while decreasing time spent in hypoglycemia–and patients experience these benefits regardless of delivery method.1,2

Continuous Information for More Insight

Unlike a blood glucose meter, which provides just a single reading, RT-CGM provides continuous, dynamic real-time information about a user's glucose levels. With readings every five minutes – up to 288 readings a day – patients will know where their glucose is headed and how fast it's getting there.

Recognized by Professional Societies

Professional societies have broadened their recommendation of RT-CGM and its application in patient care protocols in adult and pediatric type 1 and type 2 diabetes patients, including those on insulin therapy as well as oral anti-diabetic agents (OAAs).

See CGM Positioning Statment

Dexcom CGM First™

Professional societies, including the ADA, AACE and the Endocrine Society now recognize RT-CGM as a standard of care.3-5 Dexcom CGM use has been proven to both reduce A1C and decrease risk of hypoglycemia regardless of insulin delivery method.2 Optimize your patients' diabetes treatment plans and prescribe a Dexcom CGM System today.

Limitations of SMBG

With SMBG, patients may be reluctant to test for a variety of reasons, including pain and discomfort, the hassles and lack of discretion.6

How Your Patients Can Benefit

RT-CGM use may benefit your newly diagnosed patient with type 1 diabetes or your patient who has been struggling to maintain control after living with type 2 diabetes for many years. CGM can benefit a broad profile of insulin-using patients, whether they are on multiple daily injections (MDI) insulin regimen or insulin therapy.

1

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes, N Engl J Med. 2008: 359(14); 1464-1476.

2

Soupal J, Petruzelkova L, Flekac M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.

3

American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S55-S64.

4

Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. Endocr Pract.

2016;22(2):231-261.

5

Peters AL, Ahmann AJ, Battelino T, et al. Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016:jc20162534.

6

Fisher WA, Kohut T, Schachner H, Stenger P. Understanding self-monitoring of blood glucose among individuals with type 1 and type 2 diabetes: an information-motivation-behavioral skills analysis. Diabetes Educ. 2011 Jan-Feb;37(1):85-94.

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.